BioSpace News Archive

Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced two additions to its leadership team: Thomas Davis, M.D. as Chief Medical Officer and Derek Meisner, J.D. as General Counsel.

Middlefield Group is pleased to announce that special meetings of unitholders of Middlefield Healthcare & Life Sciences Dividend Fund and REIT INDEXPLUS Income Fund were held today at which approximately 99.3% of the unitholders of Life Sciences and 96.7% of the unitholders of REIT present in person or represented by proxy voted in favour of respective resolutions authorizing the tax-deferred conversions of the Funds into exchange-traded funds, which are expected to occur in mid-February 2019.

Alternate Health Corp. announced today that the Company has closed a non-brokered private placement of 12,739,000 common shares at a price of CAD$0.40 per common share for aggregate gross proceeds of CAD$5,095,000.

Astrotech Corporation announced the results of its fiscal year 2018 Annual Meeting of Shareholders held on December 7, 2018.

Astellas Pharma Inc. today announced that XOSPATA® (generic name: gilteritinib) is now available for prescription in the United States for the treatment of adult patients who have relapsed or refractory (resistant to treatment) Acute Myeloid Leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.1

Netsmart, announced it has completed a recapitalization representing a strategic minority investment by TA Associates, a leading growth private equity firm with a focus on technology and healthcare, and additional investment by existing shareholder GI Partners, a leading private equity firm.

Opportunities on the rise for acquiring a private practice as retirees outnumber graduates

The Road to Zero Coalition, managed by the National Safety Council, is pleased to announce applications are now being accepted for the 2019 Safe System Innovation Grants.

Pomerantz LLP is investigating claims on behalf of investors of YogaWorks, Inc.

Grant proposals must address factors contributing to poor birth outcomes, infant mortality